Investment
Features
FeesSafety
Academy
More
Pluang+

Compare W W Grainger Inc (GWW) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance

W W Grainger IncTrade
IDEXX Laboratories, Inc.Trade

Price performance (Past 24H)

Key statistics

W W Grainger Inc vs IDEXX Laboratories, Inc. — how do they compare? W W Grainger Inc trades at $1,400.73 (market cap $64.75B), while IDEXX Laboratories, Inc. trades at $577.63 (market cap $43.94B). The key difference: W W Grainger Inc is the larger of the two by market cap, and W W Grainger Inc pays a 0.68% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.

GWWIDXX
Market Cap
$64.75B$43.94B
Sector
TechnologyHealth
52-Week High
$1.39K$766.68
52-Week Low
$918.18$514.61
Enterprise Value
$66.84B$44.84B
Dividend Yield
0.68%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

W W Grainger Inc

GWW trades at $1,398.30, up 1.99% on the day, with a bullish technical outlook supported by moving averages and strong momentum indicators. The company reported robust Q1 2026 earnings of $11.65 per share, beating estimates, and raised its full-year guidance. Revenue growth and profitability remain solid, with a net income margin of 9.7% and ROE of 48.1% for 2025. Recent news highlights its inclusion in high-quality dividend and momentum stock lists, reflecting positive market recognition.

The outlook for GWW is positive, driven by earnings beats and upward guidance revisions, though valuation multiples like a P/E of 36.88 suggest premium pricing. Risks include competitive pressures in the industrial services sector and reliance on MRO market demand. Analyst consensus is cautious with a hold-heavy rating, but the average price target of $1,260 implies modest upside potential from current levels.

IDEXX Laboratories, Inc.

IDXX stock trades at $540.68, down 4.15% in the last session, with technical indicators showing a bearish bias. Fundamentally, the company demonstrates strong profitability with a 24.63% net margin and consistent earnings beats in recent quarters. Revenue growth continues, reaching $4.3B in 2025. Analyst sentiment remains predominantly positive with a 59% buy rating, though technical signals conflict with this fundamental strength.

The outlook balances robust fundamentals against technical weakness. Investment opportunity lies in sustained high profitability and market leadership in veterinary diagnostics, but risks include elevated valuation multiples (P/E 40.99) and bearish technical momentum that may pressure the stock near-term despite positive analyst coverage.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About W W Grainger Inc

Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.

Read more on GWW

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX